1 min read

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

On this page

Share

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

Related Articles

Explore posts connected to this topic

Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that...

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease